A5046961934- Platelet Disorders and Treatments
- Hemophilia Treatment and Research
- Antiplatelet Therapy and Cardiovascular Diseases
- Blood Coagulation and Thrombosis Mechanisms
- Heparin-Induced Thrombocytopenia and Thrombosis
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Venous Thromboembolism Diagnosis and Management
- Blood properties and coagulation
- Gastrointestinal Bleeding Diagnosis and Treatment
- Cardiovascular Disease and Adiposity
- Pregnancy and preeclampsia studies
- Liver Disease Diagnosis and Treatment
- Hemostasis and retained surgical items
- Cardiac Valve Diseases and Treatments
- Extracellular vesicles in disease
- Infective Endocarditis Diagnosis and Management
- Aortic Disease and Treatment Approaches
- Liver physiology and pathology
- Dermatological and COVID-19 studies
- COVID-19 Clinical Research Studies
- Aortic aneurysm repair treatments
- Listeria monocytogenes in Food Safety
- Adipokines, Inflammation, and Metabolic Diseases
- Hemoglobinopathies and Related Disorders
- Phagocytosis and Immune Regulation
Université de Strasbourg
2012-2025
Hôpitaux Universitaires de Strasbourg
2006-2025
Hôpital d'Hautepierre
2001-2024
Hôpital Civil, Strasbourg
2008-2023
Laboratoire d’HYdrologie et de GEochimie
2010-2020
Foundation of Cardiac Surgery Development
2015
Society of Interventional Radiology
2015
Hôpital Saint Eloi
1993-1996
Université de Montpellier
1993
Centre Hospitalier de Tourcoing
1988
Procoagulant microparticles constitute valuable hallmarks of cell damage. Microparticles also behave as cellular effectors.We hypothesized that the extent vascular damage measured by circulating could be related to severity pulmonary arterial hypertension (PAH).Circulating biomarkers and activation were in blood samples from 20 patients with PAH. Samples withdrawn occluded artery jugular vein. Peripheral venous obtained 23 control subjects. The microparticle procoagulant abilities quantified...
We sought to determine whether assessing D-Dimer might be helpful for the management of acute aortic dissection (AAD).Single-center retrospective case-control study.University Hospital Strasbourg France.Patients were 94 consecutive patients admitted our institution with confirmed AAD and in whom test had been performed at presentation. These matched controls presenting clinical suspicion dissection, which was later ruled out.Patient characteristics course analyzed.Ninety-three (99%) elevated...
In the present study, we explored microparticles involved in control of hemostatic equilibrium, i.e originating from platelet, endothelial cells and total MP defined as annexin V positive microparticles. Our aim was to analyze level procoagulant activity these normal pregnancy pregnancies complicated with preeclampsia or isolated intrauterine growth restriction. We reported increased levels platelet compared non pregnant healthy women. Number significantly together their activity....
Background The Hemophilia Functional Ability Scoring Tool (Hemo-FAST), consisting of a patient-reported outcome (PRO) part and clinician-reported (ClinRO) part, was developed as rapid effective tool to assess functional mobility in clinical practice. This study (NCT04731701) aimed validate the psychometric properties Hemo-FAST for assessment joint health people with haemophilia (PwH). Methods PwH A or B aged ≥18 years completed questionnaires including PRO short-form 36 survey (SF-36) during...
More real-world data are needed to complement existing phase III studies on the efficacy and safety of recombinant factor IX Fc fusion protein (rFIXFc) in people with haemophilia B. We report final from B-SURE study, evaluating usage effectiveness rFIXFc France. Previously treated patients (all ages/severities) received on-demand or prophylactic during B-SURE. Annualised bleeding rate (ABR), injection frequency (IF) consumption (FC) were prospectively evaluated for prophylaxis (primary...
The obstetrical follow-up of patients with a severe hypofibrinogenemia requires multidisciplinary collaboration because potential maternal-fetal complications (recurrent miscarriages, intrauterine fetal demise, post-partum hemorrhage, thrombosis). We report the management multiparous patient congenital associated platelet disorder (abnormal phospholipid externalization). A therapeutic strategy based on biweekly administration fibrinogen concentrates enoxaparin and aspirin allowed maintenance...
Background: This case report investigates the effects of sotorasib treatment in a patient with acquired von Willebrand syndrome (AVWS) associated monoclonal gammopathy undetermined significance (MGUS), who subsequently developed non-small-cell lung carcinoma (NSCLC) KRAS G12C mutation. Case Presentation: The patient, 79-year-old male, presented prolonged history recurrent lower gastrointestinal bleeding attributed to digestive angiodysplasia, which had persisted for over 30 years. AVWS was...
Background A triple-secured plasma-derived von Willebrand factor (pdVWF) almost devoid of VIII (FVIII):WILFACTIN®, was approved in France 2003, and then other countries for the treatment patients with disease (VWD). Objective To investigate long-term safety efficacy product real-life over first 5 post-approval years. Patients/Methods This prospective, observational, national post-marketing study (PMS) enrolled all ages VWD types. Patients were observed up to 3 years treated one or more...
Introduction:During the treatment of Hemophilia A patients without inhibitors using factor VIII (FVIII) activity-mimicking bispecific antibody Emicizumab (Hemlibra) bleeding episodes can occur, which require administration FVIII concentrates to restore hemostasis.Because Emicizumab's specificity for human coagulation factors, levels in presence be measured by a chromogenic activity assay based on bovine reagents.However, novel agents could lack this and thus not allow successfully follow...
Impaired platelet responsiveness to clopidogrel identified by flow cytometric vasodilator-stimulated phosphoprotein (VASP) phosphorylation in patients with subacute stent thrombosis -
We retrospectively analysed the data files of 171 adults and 87 children/adolescents with severe haemophilia, except for 14 patients (moderate; minor) (1), to develop a global population pharmacokinetic (PK) model eight factors VIII (FVIII) that could estimate individual PK parameters targeting desired level FVIII activity (FVIII:C); (2) compare half-life (HL) in switching from standard (SHL) an extended (EHL) evaluate relevance switch. One-stage clotting assay measurement (FVIII:C, IU/mL)...
Patients with symptomatic von Willebrand disease (VWD) should be offered long-term prophylaxis (LTP) to prevent recurrent bleedings. Our objective was evaluate the effectiveness and safety of Voncento®, a plasma-derived FVIII/VWF concentrate (ratio 1:2.4), administrated in LTP.We included patients from OPALE study (May 2016 April 2021), French multicenter observational following inherited VWD, who received Voncento® LTP during period.Among 130 OPALE-study patients, 23 (12 women) were...
Abstract Introduction It is necessary to gain insights into adherence healthcare in people with severe haemophilia (PwSH), especially during the transition from paediatric adult care, which an important phase lives of young childhood chronic disease. This can be considered as a marker successful transition. Objectives The main objective quantitative TRANSHEMO project was compare between adolescents and adults (YAs) haemophilia. secondary identify determinants (facilitators barriers) this...
Abstract Introduction Acquired von Willebrand syndrome (AVWS) is a rare haemorrhagic disorder. The prophylaxis and treatment of bleeding before surgery are complex. Since 2018, new recombinant VWF (rVWF) concentrate that contains no factor VIII (FVIII) but high amount molecular weight multimers has been available in France. Aim To describe the real‐world experience using rVWF non‐surgical surgical procedures patients with AVWS. Methods Fifteen episodes seven 16 surgeries 10 were...